These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17975007)

  • 1. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
    Suzuki T; Fujii A; Ohya J; Amano Y; Kitano Y; Abe D; Nakamura H
    Cancer Sci; 2007 Dec; 98(12):1977-84. PubMed ID: 17888033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
    Sirica AE
    World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.
    Jung J; Schneider EL; Zhang W; Song H; Zhang M; Chou W; Meher N; VanBrocklin HF; Barcellos-Hoff MH; Ozawa T; Gilbert MR; Santi DV
    Sci Rep; 2024 Jun; 14(1):14175. PubMed ID: 38898077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition.
    Ogden S; Carys K; Ahmed I; Bruce J; Sharrocks AD
    Oncogene; 2022 Oct; 41(43):4808-4822. PubMed ID: 36153371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction to: TAS2940, A novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Cancer Sci; 2024 May; 115(5):1718. PubMed ID: 38270288
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
    Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y
    J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revoking the privilege: targeting HER2 in the central nervous system.
    Contessa JN; Hamstra DA
    Mol Pharmacol; 2008 Feb; 73(2):271-3. PubMed ID: 17981994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.
    Schepetkin IA; Plotnikov MB; Khlebnikov AI; Plotnikova TM; Quinn MT
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.
    Streets AJ; Magayr TA; Huang L; Vergoz L; Rossetti S; Simms RJ; Harris PC; Peters DJ; Ong AC
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F577-F588. PubMed ID: 28077374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
    Fabi A; Malaguti P; Vari S; Cognetti F
    J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinomatous myelitis and meningitis after a squamous cell carcinoma of the lip.
    Pougnet I; Murati A; Sarran A; Viens P; Sabatier R
    Case Rep Oncol; 2014 Jan; 7(1):33-8. PubMed ID: 24575013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.
    Forster N; Saladi SV; van Bragt M; Sfondouris ME; Jones FE; Li Z; Ellisen LW
    Dev Cell; 2014 Jan; 28(2):147-60. PubMed ID: 24412575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.
    Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y
    Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.
    Sysa-Shah P; Xu Y; Guo X; Belmonte F; Kang B; Bedja D; Pin S; Tsuchiya N; Gabrielson K
    PLoS One; 2012; 7(8):e42805. PubMed ID: 22912742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastases as preventive and therapeutic targets.
    Steeg PS; Camphausen KA; Smith QR
    Nat Rev Cancer; 2011 May; 11(5):352-63. PubMed ID: 21472002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
    Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
    MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
    Gulati S; Ytterhus B; Granli US; Gulati M; Lydersen S; Torp SH
    Diagn Pathol; 2010 Mar; 5():18. PubMed ID: 20331873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood medulloblastoma: current status of biology and treatment.
    Klesse LJ; Bowers DC
    CNS Drugs; 2010 Apr; 24(4):285-301. PubMed ID: 20297854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.